Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK5VM1
|
|||
| Drug Name |
VM1500A
|
|||
| Synonyms |
867365-76-2; RO-0335; RO0335; Depulfavirine; Ro 0335; VM-1500A; 2-(4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl)-N-(2-chloro-4-sulfamoylphenyl)acetamide; 2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide; ZP6H7RDZ5Q; RO-4970335; VM1500A; N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoroBenzeneacetamide; RO4970335; Benzeneacetamide, N-(4-(aminosulfonyl)-2-chlorophenyl)-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-; Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-; Depulfavirine [INN]; UNII-ZP6H7RDZ5Q; SCHEMBL2638090; CHEMBL4438269; EX-A892; Ro-0335 pound>>Ro0335; BCP28161; AKOS027338665; 2-[4-bromo-3-(3-chloro-5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-sulfamoyl-phenyl)acetamide; HY-13053; MS-30329; CS-0003172; FT-0700384; A922653; J-690367; Methyl (2-{(R)-(3-chlorophenyl)[(3R)-1-({(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl}carbamoyl)-3-piperidinyl]metho xy}ethyl)carbamate; VM5
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24; ICD-9: 42] | Phase 2/3 | [1] | |
| Company |
Viriom
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H13BrCl2FN3O4S
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1S(=O)(=O)N)Cl)NC(=O)CC2=C(C(=C(C=C2)Br)OC3=CC(=CC(=C3)C#N)Cl)F
|
|||
| InChI |
InChI=1S/C21H13BrCl2FN3O4S/c22-16-3-1-12(20(25)21(16)32-14-6-11(10-26)5-13(23)8-14)7-19(29)28-18-4-2-15(9-17(18)24)33(27,30)31/h1-6,8-9H,7H2,(H,28,29)(H2,27,30,31)
|
|||
| InChIKey |
SBUUICLVCQQMFP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05204394) Multicenter, Open-label, Randomized, Active Control Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy. U.S.National Institutes of Health. | |||
| REF 2 | Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida(?)) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1056-1060. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.